Lutathera + Gallium 68 Dotatate
Phase 1Recruiting 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
Mar 17, 2021 → Sep 1, 2027
NCT ID
NCT04609592About Lutathera + Gallium 68 Dotatate
Lutathera + Gallium 68 Dotatate is a phase 1 stage product being developed by Novartis for Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04609592. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor.
What happened to similar drugs?
0 of 3 similar drugs in Gastroenteropancreatic Neuroendocrine Tumor were approved
Approved (0) Terminated (0) Active (3)
🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04609592 | Phase 1 | Recruiting |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 27 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 32 |
| Lutathera® | Novartis | Pre-clinical | 30 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 29 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 32 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 29 |
| Lanreotide autogel | Ipsen | Phase 3 | 37 |